CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

/PRNewswire/ -- Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children...

Related Keywords

Japan ,Paris ,France General ,France ,Georged Yancopoulos ,Regeneron Velocimmune ,Regeneron Pharmaceuticals Inc ,European Commission Of Dupixent ,Twitter ,Regeneron Genetics Center ,European Commission ,Dupilumab Development Program ,Regeneron Velocimmune Technology ,Nasdaq ,Teva Pharmaceutical Industries Ltd ,Exchange Commission ,European Union ,European Medicines Agency ,Medicinal Products ,Human Use ,New England Journal ,Chief Scientific Officer George ,Prescribing Informationincluding Patient ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Teva Pharmaceutical Industries ,Nc ,